Emmaus Life Sciences, Inc. (EMMA) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE, CA 90503 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 9/30/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 2,547 | 2,021 | 2,279 | 2,487 | 29,698 | 3,255 | |||
| Cash and cash equivalent | 2,547 | 2,021 | 2,279 | 2,487 | 1,769 | 3,255 | |||
| Short-term investments | 27,929 | ||||||||
| Receivables | 5,524 | 375 | 1,040 | 198 | 2,150 | 63 | |||
| Inventory, net of allowances, customer advances and progress billings | 1,711 | 2,379 | 4,392 | 7,087 | 7,971 | ||||
| Inventory | 1,711 | 2,379 | 4,392 | 7,087 | 7,971 | ||||
| Prepaid expense | 536 | 467 | 326 | 388 | 735 | 58 | |||
| Other current assets | 596 | 449 | 394 | 1,097 | 667 | ||||
| Other undisclosed current assets | 595 | 598 | 660 | 135 | |||||
| Total current assets: | 11,509 | 6,289 | 9,091 | 11,257 | 41,221 | 3,511 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 2,337 | 2,799 | 3,485 | 4,072 | 4,474 | ✕ | |||
| Property, plant and equipment | 59 | 75 | 147 | 120 | 151 | 111 | |||
| Long-term investments and receivables | 18,828 | 17,616 | |||||||
| Long-term investments | 18,828 | 17,616 | |||||||
| Intangible assets, net (including goodwill) | 1,503 | ||||||||
| Goodwill | 1,387 | ||||||||
| Intangible assets, net (excluding goodwill) | 117 | ||||||||
| Other noncurrent assets | 296 | 263 | 295 | 296 | 285 | 27 | |||
| Other undisclosed noncurrent assets | 20,978 | 19,971 | 26,100 | 43,791 | 13,325 | ||||
| Total noncurrent assets: | 23,670 | 41,936 | 47,643 | 48,279 | 18,235 | 1,641 | |||
| TOTAL ASSETS: | 35,179 | 48,225 | 56,734 | 59,536 | 59,456 | 5,152 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 17,725 | 13,549 | 9,189 | 7,460 | 11,498 | 620 | |||
| Interest and dividends payable | ✕ | ✕ | ✕ | 579 | 627 | 991 | 4 | ||
| Accounts payable | 5,887 | 3,785 | 2,583 | 2,023 | 7,277 | 347 | |||
| Accrued liabilities | 8,174 | 7,239 | 5,936 | 4,769 | 3,188 | 269 | |||
| Other undisclosed accounts payable and accrued liabilities | 3,664 | 2,525 | 91 | 41 | 42 | ||||
| Debt | 16,383 | 14,655 | 1,200 | 6,280 | 11,601 | 1 | |||
| Deferred compensation liability | 175 | ||||||||
| Derivative instruments and hedges, liabilities | 65 | 70 | 1,503 | 1,071 | 38 | ||||
| Other liabilities | 14,681 | 12,917 | 4,404 | 2,706 | 5,748 | ||||
| Due to related parties | ✕ | ✕ | 2,367 | 800 | 30 | ||||
| Other undisclosed current liabilities | 12,653 | 10,765 | 20,004 | 5,865 | 3,942 | 339 | |||
| Total current liabilities: | 61,507 | 54,323 | 37,100 | 23,382 | 32,827 | 1,165 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 4,061 | 6,620 | 3,932 | 590 | |||||
| Long-term debt, excluding current maturities | 800 | 3,150 | 588 | ||||||
| Capital lease obligations | ✕ | ✕ | ✕ | ✕ | ✕ | ✕ | 2 | ||
| Liabilities, other than long-term debt | 19,202 | 27,613 | 33,173 | 34,470 | 33,750 | ||||
| Due to related parties | ✕ | ✕ | 3,346 | ||||||
| Other liabilities | 17,363 | 21,714 | 33,173 | 34,470 | 33,750 | ||||
| Operating lease, liability | 1,839 | 2,553 | 3,261 | 3,470 | 3,932 | ✕ | |||
| Other undisclosed noncurrent liabilities | 2,226 | 380 | 3,850 | 222 | 110 | ||||
| Total noncurrent liabilities: | 21,428 | 27,993 | 41,084 | 41,312 | 37,682 | 700 | |||
| Total liabilities: | 82,935 | 82,316 | 78,184 | 64,694 | 70,509 | 1,865 | |||
| Equity | |||||||||
| Equity, attributable to parent | (47,756) | (34,091) | (21,450) | (5,158) | (11,053) | 4,021 | |||
| Preferred stock | 1 | ||||||||
| Common stock | 62 | 50 | 49 | 49 | 48 | 7 | |||
| Additional paid in capital | 225,333 | 220,815 | 220,022 | 218,728 | 215,207 | 89,258 | |||
| Accumulated other comprehensive income (loss) | (160) | (2,619) | (255) | 1,144 | (79) | ||||
| Accumulated deficit | (256,122) | (252,337) | (241,266) | (225,079) | (226,229) | (85,245) | |||
| Receivable from shareholders or affiliates for issuance of capital stock | (16,869) | ||||||||
| Equity, attributable to noncontrolling interest | (734) | ||||||||
| Total equity: | (47,756) | (34,091) | (21,450) | (5,158) | (11,053) | 3,287 | |||
| TOTAL LIABILITIES AND EQUITY: | 35,179 | 48,225 | 56,734 | 59,536 | 59,456 | 5,152 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 9/30/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 29,597 | 18,390 | 20,610 | 23,167 | 22,752 | 1,316 | ||
| Gain (loss) on disposition of assets for financial service operations | 7,672 | (21,432) | ||||||
| Realized investment losses | (21,947) | |||||||
| Cost of revenue | (1,342) | (2,588) | (3,312) | (2,248) | (1,094) | (827) | ||
| Gross profit: | 28,255 | 15,802 | 17,298 | 20,919 | 21,658 | 488 | ||
| Operating expenses | (24,715) | (22,388) | (23,426) | (20,951) | (26,170) | (10,733) | ||
| Operating income (loss): | 3,540 | (6,586) | (6,128) | (32) | (4,512) | (10,245) | ||
| Nonoperating expense | (1,767) | (2,662) | (2,017) | (86) | ||||
| Loss, foreign currency transaction, before tax | (1,767) | (2,662) | (2,017) | |||||
| Interest and debt expense | (8,204) | (5,514) | (3,466) | (7,414) | (31,404) | |||
| Loss from continuing operations before equity method investments, income taxes: | (6,431) | (14,762) | (11,611) | (7,446) | (35,916) | (10,331) | ||
| Loss from equity method investments | (1,713) | (1,913) | (2,733) | (2,060) | (414) | |||
| Other undisclosed income (loss) from continuing operations before income taxes | 4,352 | 6,110 | (1,577) | 10,479 | (18,348) | |||
| Income (loss) from continuing operations before income taxes: | (3,792) | (10,565) | (15,921) | 973 | (54,678) | (10,331) | ||
| Income tax expense (benefit) | 59 | (60) | (25) | 381 | (164) | (2) | ||
| Income (loss) from continuing operations: | (3,733) | (10,625) | (15,946) | 1,354 | (54,842) | (10,333) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | (15,946) | 1,354 | (54,842) | (10,333) | |
| Net income (loss): | (3,733) | (10,625) | (15,946) | 1,354 | (54,842) | (10,333) | ||
| Net loss attributable to noncontrolling interest | (734) | |||||||
| Other undisclosed net income attributable to parent | 1,469 | |||||||
| Net income (loss) attributable to parent: | (3,733) | (10,625) | (15,946) | 1,354 | (54,842) | (9,599) | ||
| Preferred stock dividends and other adjustments | (49) | |||||||
| Net income (loss) available to common stockholders, diluted: | (3,733) | (10,625) | (15,946) | 1,354 | (54,842) | (9,648) | ||
Comprehensive Income ($ in thousands)
| 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 9/30/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (3,733) | (10,625) | (15,946) | 1,354 | (54,842) | (10,333) | ||
| Other comprehensive income (loss) | 2,459 | (2,364) | (1,399) | 1,223 | (10) | |||
| Comprehensive income (loss): | (1,274) | (12,989) | (17,345) | 2,577 | (54,852) | (10,333) | ||
| Comprehensive loss, net of tax, attributable to noncontrolling interest | (734) | |||||||
| Comprehensive income (loss), net of tax, attributable to parent: | (1,274) | (12,989) | (17,345) | 2,577 | (54,852) | (11,068) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.